Skip Navigation


Europace Advance Access originally published online on July 11, 2008
Europace 2008 10(8):1006-1008; doi:10.1093/europace/eun180
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
10/8/1006    most recent
eun180v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Fox, D. J.
Right arrow Articles by Krahn, A. D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Fox, D. J.
Right arrow Articles by Krahn, A. D.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Published on behalf of the European Society of Cardiology. All rights reserved. © The Author 2008. For permissions please email: journals.permissions@oxfordjournals.org

SHORT COMMUNICATIONS

Reduction of complex ventricular ectopy and improvement in exercise capacity with flecainide therapy in Andersen–Tawil syndrome

David J. Fox*, George J. Klein, Angelika Hahn, Allan C. Skanes, Lorne J. Gula, Raymond K. Yee, Rajesh N. Subbiah and Andrew D. Krahn*

Division of Cardiology, Department of Medicine, University of Western Ontario, London, Ontario, Canada

Andersen–Tawil syndrome (ATS) is a rare inherited autosomal disorder characterized by the clinical triad of ventricular arrhythmias, hypokalaemic periodic paralyses, and skeletal developmental abnormalities, resulting in dysmorphic features. Although ATS patients have a high incidence of ventricular arrhythmias, the occurrence of sudden cardiac death is rare. In this report, we describe the successful use of flecainide in an ATS patient with a considerable ventricular arrhythmia burden who had not demonstrated any response to conventional β-blocker therapy used in conjunction with potassium (K+) supplementation.

Key Words: Flecainide, Exercise, Repolarization, Ectopy

* Corresponding authors. London Health Sciences Centre, University Campus, 339 Windermere Road, Room 3HE-6, London, Ontario, Canada N6A 5A5. Tel: +1 519 663 3746; fax: +1 519 663 3786 (A.D.K.), Tel/fax: +1 519 685 8500 (D.J.F.). E-mail address: akrahn{at}uwo.ca (A.D.K.) or david.j.fox{at}talk21.com (D.J.F.)

Manuscript submitted 25 May 2008. Accepted after revision 10 June 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.